Abstract: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of an immune cell, a method for stabilizing the cell membrane of an immune cell, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.
Abstract: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.
Abstract: Methods for treating cutaneous inflammation are described. Also described is a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.
Abstract: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, methods for blocking IgE activation and for stabilizing the cell membrane of lymphocytes, mast cells, basophils, macrophages, monocytes, eosinophils, neutrophils, and the like, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.
Type:
Grant
Filed:
November 19, 2007
Date of Patent:
August 9, 2011
Assignee:
Mowycal Lending, LLC
Inventors:
John C. Houck, Mary MacDonald, legal representative, James Clagett
Abstract: The present invention provides a biochip microarray, with multiple properties for use in identification of gene- and protein-induction or repression by drugs, the evaluation of efficacy and toxicity of any drug of choice, prediction of efficacy and toxicity of newly-discovered drugs, families of drugs or classes of drugs. Experimental information acquired from the biochip is inputted into a Drug-Gene-Protein-Biology (DGPB) database from which experimental data can be mined and analyzed based on the users preferences. A method for predicting the effect of a test composition for the treatment of a disease also is described. An animal model for the disease is selected. A biochip array for evaluating the effect of the test composition for the treatment of the disease is provided. The test composition is tested in the animal model to obtain a first set of biological markers representative of the effect of the test composition in the animal model.